The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://tessmkzg821801.wikicarrier.com/1035407/retatrutide_vs_tirzepatide_a_comparative_analysis